Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.875
+0.085 (2.24%)
Feb 27, 2026, 3:09 PM EST - Market open
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 975 employees as of December 31, 2025. The number of employees increased by 137 or 16.35% compared to the previous year.
Employees
975
Change (1Y)
137
Growth (1Y)
16.35%
Revenue / Employee
$270,258
Profits / Employee
-$401,003
Market Cap
1.60B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 975 | 137 | 16.35% |
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 952 |
| Immunocore Holdings | 493 |
| Ardelyx | 489 |
| Intellia Therapeutics | 403 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 268 |
| Biohaven | 256 |
| uniQure | 209 |
IOVA News
- 1 day ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 2 days ago - Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) - Seeking Alpha
- 3 days ago - Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy - Benzinga
- 3 days ago - Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas - GlobeNewsWire
- 3 days ago - Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates - GlobeNewsWire
- 6 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 - GlobeNewsWire